For example, data from our previous investigations suggest that 18F-labelled PSMA ligands are at least non-inferior to 68Ga-labelled PSMA ligands in detecting tumour lesions and offer some further advantages in detecting smaller tumour lesions at low PSA levels [20, 21, 22]. This evidence concerns the gene FOLH1 and neoplasm.